摘要
免疫治疗一直是肿瘤治疗的热点,随着基因重组技术的发展及人们对肿瘤发病机制的深入认识,嵌合抗原受体T细胞(CAR-T)过继免疫疗法得以在临床试验研究中开展。CAR-T治疗难治复发急性淋巴细胞白血病、难治进展期淋巴瘤、难治复发慢性淋巴细胞白血病取得了突破性的进展,获得了令人瞩目的效果,但仍有部分患者维持时间短暂或对治疗无反应或发生严重的细胞因子释放综合征;对于多发性骨髓瘤、难治复发急性髓系白血病CAR-T疗效还不满意,在这些方面还存在许多挑战及机遇,任重而道远。本文就CAR-T细胞治疗在血液肿瘤中的研究进展做一述评。
Since the breakthrough made in gene recombination technique and deeper understanding on mechanism of tumorigenesis, immunotherapy has moved into the mainstream of oncology treatment. Chimeric antigen receptor （CAR） T cell adoptive immunotherapy has become a promising therapy for cancer. Early clinical trials using CAR T cells for the treatment of patients with refractory hematological malignancies achieved promising efficacy. Despite these wonderful clinical outcome, there still exist many patients could＇ d get continuous remission or show no response to CAR-T therapy and responses among patients with multiple myeloma or refractory and relapsed acute myeloid leukemia haven＇t win great satisfaction. Additionally, cytokine release syndrome is the most significant and life-threatening toxicity which needs more clinical experiences. All above may guide new challenges and important discoveries in immunotherapy of hematological malignancies.
出处
《西部医学》
2016年第10期1333-1338,共6页
Medical Journal of West China
基金
陕西省科技统筹创新工程计划项目(2014TCL 03-02)
关键词
CAR-T
细胞免疫治疗
血液肿瘤
Chimeric antigen receptor T Cell immunotherapy
Hematological malignancy
